...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hypertension research: Official journal of the Japanese Society of Hypertension >Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension--the Nifedipine and Candesartan Combination (NICE-Combi) Study.
【24h】

Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension--the Nifedipine and Candesartan Combination (NICE-Combi) Study.

机译：高血压治疗的成本效益分析：硝苯地平与坎地沙坦低剂量联合治疗原发性高血压患者-硝苯地平与坎地沙坦组合（NICE-Combi）研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Societal interest in pharmaco-economic analysis is increasing in Japan. In this study, the cost-effectiveness of low-dose combination therapy with controlled release nifedipine plus candesartan and up-titrated monotherapy with candesartan was estimated, based on the results of the NICE-Combi study. The NICE-Combi study was a double-blind, parallel arm, randomized clinical trial to compare the efficacy of low-dose combination therapy of controlled release nifedipine (20 mg/day) plus candesartan (8 mg/day) vs. up-titrated monotherapy of candesartan (12 mg/day) on blood pressure control in Japanese patients with mild to severe essential hypertension who were not sufficiently controlled by the conventional dose of candesartan (8 mg/ day). The incremental cost effectiveness of each cohort during the 8-week randomization period was compared, from the perspective of a third-party payer (i.e., insurers). The average total cost per patient was 29,943 Japanese yen for the combination therapy group and 33,182 Japanese yen for the candesartan monotherapy group, while the rate of achievement of the target blood pressure was significantly higher in the combination therapy group than in the up-titrated monotherapy group. In the combination therapy group, higher efficacy and lower incremental treatment cost ("Dominance") were observed when compared to the monotherapy group. The sensitivity analyses also supported the results. In conclusion, these results suggest that combination therapy with controlled release nifedipine and low-dose candesartan (8 mg) is "dominant" to up-titrated candesartan monotherapy for the management of essential hypertension. This conclusion was robust to sensitivity analysis.
机译：日本对药物经济学分析的社会关注与日俱增。在这项研究中，根据NICE-Combi研究的结果，估计了低剂量联合控制的硝苯地平加坎地沙坦联合疗法和坎地沙坦单药联合疗法的成本效益。 NICE-Combi研究是一项双盲，平行臂随机临床试验，比较了控释硝苯地平（20 mg /天）加坎地沙坦（8 mg /天）与高剂量联合低剂量联合治疗的疗效对日本轻度至重度原发性高血压患者的坎地沙坦单药治疗（12 mg /天），他们无法通过常规剂量的坎地沙坦（8 mg /天）充分控制血压。从第三方付款人（即保险人）的角度，比较了每个队列在8周随机化期间内增量成本效益。联合疗法组每位患者的平均总费用为29,943日元，坎地沙坦单一疗法组为33,182日元，而联合疗法组的目标血压达到率显着高于加强型单一疗法组。与单一疗法组相比，在联合疗法组中观察到更高的疗效和更低的增量治疗费用（“优势”）。敏感性分析也支持结果。总之，这些结果表明，控释硝苯地平和小剂量坎地沙坦（8毫克）的联合治疗对于加强原发性坎地沙坦单药治疗的原发性高血压是“主要”。这个结论对敏感性分析是有力的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号